The manufacturer will provide enough of the drug to supply 200,000 patients annually for more than a decade. Critics said it would not be enough to end the AIDS epidemic and questioned the company’s motives.
Published: May 9, 2019 at 02:00AM
from NYT Health https://nyti.ms/2VRY6qm